Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared on X:
“Tarlatamab in ES-SCLC: The Next Challenge Is Implementation.
Important debates in Porto highlighted two key questions: optimal timing and where T-cell engagers should be delivered.
DeLLphi-305 demonstrated a remarkable OS benefit with tarlatamab + durvalumab maintenance:
21.1 vs 12.7 months / HR 0.42
CRS occurred in nearly 50% of patients, but severe events were uncommon.
The evidence supports maintenance treatment in eligible patients. The next challenge is ensuring safe and equitable access.
Should tarlatamab be restricted to specialized centers, or delivered through trained oncology centers with appropriate CRS/ICANS management pathways?”
You can also read:
DeLLphi-305: Tarlatamab–Durvalumab Redefines First-Line Maintenance in Extensive-Stage SCLC
